Cardiac Dimensions, Inc. news

Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced the mention of their Carillon Mitral Contour System in the 2021 European Society of Cardiology (ESC) Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. In addition, the Carillon Mitral Contour System can now be considered under the new Class IIb 2021 Guidelines for the Management of Va

Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced the launch of the U.S. pivotal study The EMPOWER Trial.

The EMPOWER Trial is evaluating the Carillon Mitral Contour System® for the treatment of heart failure patients with early-stage functional mitral regurgitation (FMR). This blinded, randomized trial will compare the Carillon treatment to a sham-c

Cardiac Dimensions announced a published second individual patient data meta-analysis demonstrating clinically significant outcomes for the Carillon Mitral Contour System®. This publication, in addition to the several others recently published on the Carillon device, continues the series of excellent results for this transcatheter-based indirect annuloplasty device.

Both of the published meta-analyses were conducted from three prospective, core lab reviewed, CEC/DSMB adjudicated a

Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, today announced the election of Robert White as an independent director to its Board of Directors. Mr. White is a veteran medical technology executive, innovator and strategist with nearly 30 years of experience leading early-stage companies and Fortune 500 business units within the medical technology sector.

“We a

Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, today announced the company has closed a $17.5 million Series C financing. All existing shareholders participated in the round including Aperture Venture Partners, Arboretum Ventures, Hostplus, Life Sciences Partners, Lumira Ventures, and M. H. Carnegie & Co.

The financing will be used to accelerate commercial s